199458-37-2

Upstream product

• 145298-15-3 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-formyl-ethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 

Downstream Products

• 199471-32-4 (S)-2-(4-{2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-[8-(bis-benzyloxy-phosphoryloxy)-octanoyloxymethyl]-ethyl}-benzoylamino)-pentanedioic acid di-tert-butyl ester 
• 199471-33-5 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-(8-phosphonooxy-octanoyloxymethyl)-ethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 
• 199471-31-3 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-(8-hydroxy-octanoyloxymethyl)-ethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 
• 199535-56-3 (S)-2-{4-[2-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-yl)-1-bromo-1-bromomethyl-ethyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 
• 199535-46-1 (S)-2-{4-[1-(2-Amino-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-vinyl]-benzoylamino}-pentanedioic acid di-tert-butyl ester 

Relevant academic research and scientific papers

Functionalized analogues of 5,8,10-trideazafolate as potential inhibitors of GAR Tfase or AICAR Tfase

A series of TDAF-based analogues of 10-formyl-tetrahydrofolic acid are examined in efforts to explore the formyl transfer region of GAR Tfase and AICAR Tfase.